April 30, 2021 -- Gene therapy tools manufacturer Progen Biotechnik has signed a nonexclusive distribution agreement with Thermo Fisher Scientific.
Under the agreement, Thermo Fisher will offer a choice of 371 primary antibodies globally. Among them are top-selling products in biomedical research and development, such as lipid metabolism, cytoskeleton, cell adhesion, and oncology. The antibodies will be available with full service and support from Thermo Fisher.
Progen's portfolio includes over 1,000 primary and secondary antibodies for basic and applied life science research.